Research programme: arenicin-3 antibacterials - Adenium Biotech
Alternative Names: AA 139; AA230; Arenicin-3; NZ 17000; NZ 17143; NZ 17211; NZ17074Latest Information Update: 28 Jan 2018
At a glance
- Originator Novozymes A/S
- Developer Adenium Biotech; Novozymes A/S
- Class Peptides
- Mechanism of Action Bacterial outer membrane protein modulators; Bacterial protein inhibitors; Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gonorrhoea; Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for preclinical development in Intra-abdominal-infections in Denmark (IV)
- 28 Jan 2018 No recent reports of development identified for research development in Gonorrhoea in Denmark (IV)
- 16 Jul 2016 No development reported - Preclinical for Nosocomial pneumonia in Denmark (Inhalation)